Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819354 | 0.84 | CYP2C9 (0.44) | MGLLHCRTR1HCRTR2CYP2C9CYP2C19 | |
| SCHEMBL13287245 | 0.82 | SLC6A2 (0.46) | MGLLCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL2819356 | 0.81 | CYP2C9 (0.46) | MGLLHCRTR1HCRTR2CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL2820762 | 0.81 | SLC6A2 (0.45) | MGLLCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL2818668 | 0.80 | SPR (0.45) | MGLLHCRTR1HCRTR2CYP2C9CYP2C19 | |
| SCHEMBL27633969 | 0.77 | TRPV1 (0.43) | HCRTR1HCRTR2CYP2C9CYP2C19P2RX7 | |
| SCHEMBL939432 | 0.75 | SCD (0.52) | SCD | |
| SCHEMBL12894564 | 0.74 | SCD (0.59) | MGLLCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL4635407 | 0.69 | CYP2C9 (0.52) | MGLLCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL13983799 | 0.68 | SCD (0.62) | MGLLCYP2C9CYP2C19HTR2BMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010075356-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160323-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160323-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | MGLL 155/4885HCRTR1 3143/4885HCRTR2 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.